Cross-sectional and longitudinal atrophy is preferentially associated with tau rather than amyloid β positron emission tomography pathology

Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring
Brian A GordonTammie L S Benzinger

Abstract

Structural magnetic resonance imaging is a marker of gray matter health and decline that is sensitive to impaired cognition and Alzheimer's disease pathology. Prior work has shown that both amyloid β (Aβ) and tau biomarkers are related to cortical thinning, but it is unclear what unique influences they have on the brain. Aβ pathology was measured with [18F] AV-45 (florbetapir) positron emission tomography (PET) and tau was assessed with [18F] AV-1451 (flortaucipir) PET in a population of 178 older adults, of which 123 had longitudinal magnetic resonance imaging assessments (average of 5.7 years) that preceded the PET acquisitions. In cross-sectional analyses, greater tau PET pathology was associated with thinner cortices. When examined independently in longitudinal models, both Aβ and tau were associated with greater antecedent loss of gray matter. However, when examined in a combined model, levels of tau, but not Aβ, were still highly related to change in cortical thickness. Measures of tau PET are strongly related to gray matter atrophy and likely mediate relationships between Aβ and gray matter.

Associated Clinical Trials

Apr 10, 2015·Tammie L. S. Benzinger, MD, PhD

References

Sep 14, 2000·Proceedings of the National Academy of Sciences of the United States of America·B Fischl, A M Dale
May 10, 2006·Archives of Neurology·Liana G ApostolovaPaul M Thompson
Dec 26, 2008·Neurology·Akram BakkourBradford C Dickerson
Apr 8, 2010·Annals of Neurology·Gaël ChételatUNKNOWN Australian Imaging Biomarkers and Lifestyle Research Group
Apr 15, 2011·Neurology·B C DickersonL Detoledo-Morrell
Aug 10, 2011·Archives of Neurology·Mert R SabuncuUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Jan 18, 2012·NeuroImage·Bruce Fischl
Jan 26, 2012·BMC Medical Research Methodology·Emily A Blood, Debbie M Cheng
Feb 4, 2012·Neurology·G ChételatUNKNOWN AIBL Research Group
Mar 21, 2012·NeuroImage·Martin ReuterBruce Fischl
Jul 13, 2012·The New England Journal of Medicine·Randall J BatemanUNKNOWN Dominantly Inherited Alzheimer Network
Nov 6, 2012·NeuroImage·Jorge L Bernal-RusielUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Dec 14, 2012·Journal of Alzheimer's Disease : JAD·David T ChienHartmuth C Kolb
Feb 16, 2013·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Chun-Fang XiaHartmuth C Kolb
May 25, 2013·NeuroImage·Jorge L Bernal-RusielUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Nov 14, 2013·PloS One·Yi SuTammie L S Benzinger
Dec 9, 2014·NeuroImage·Matthias BrendelUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Apr 8, 2015·PloS One·Yi SuTammie L S Benzinger
May 6, 2015·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Stephanie A SchultzOzioma C Okonkwo
Oct 28, 2015·Annals of Neurology·Keith A JohnsonReisa Sperling
Mar 5, 2016·Brain : a Journal of Neurology·Sebastian PalmqvistUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Mar 5, 2016·Neuron·Michael SchöllWilliam J Jagust
Mar 11, 2016·Brain : a Journal of Neurology·Rik OssenkoppeleGil D Rabinovici
May 14, 2016·Science Translational Medicine·Matthew R BrierBeau M Ances
Jun 12, 2016·Brain : a Journal of Neurology·Brian A GordonTammie L S Benzinger
Jun 15, 2016·Acta Neuropathologica Communications·Val J LoweMelissa E Murray
Jul 1, 2016·Neurology·Hanna ChoMyung Sik Lee
Jul 12, 2016·Annals of Neurology·Andrei G VlassenkoAnne M Fagan
Jul 31, 2016·Neurology·Jasmeer P ChhatwalKeith A Johnson
Jan 18, 2017·Annals of Clinical and Translational Neurology·Gérard N BischofUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Apr 11, 2017·Alzheimer Disease and Associated Disorders·Gregory S DayJohn C Morris
Jul 27, 2017·EMBO Molecular Medicine·Niklas MattssonOskar Hansson

❮ Previous
Next ❯

Citations

Feb 13, 2019·Brain : a Journal of Neurology·Brian A GordonTammie L S Benzinger
Feb 16, 2019·Acta Neuropathologica Communications·Santosh JadhavNorbert Zilka
Nov 28, 2019·Journal of Alzheimer's Disease : JAD·Eliot J DavidowitzJames G Moe
Jan 8, 2020·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Christa DangUNKNOWN AIBL Research Group
Jul 6, 2019·Alzheimer's Research & Therapy·Tessa TimmersBart N M van Berckel
Oct 6, 2020·Journal of Alzheimer's Disease : JAD·Hyemin JangUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Oct 24, 2020·Brain : a Journal of Neurology·Clifford R JackRonald C Petersen
Sep 3, 2019·Journal of Alzheimer's Disease : JAD·Arnaud CharilAdam J Schwarz
Jan 26, 2021·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Joel SimrénNicholas J Ashton
Oct 31, 2020·Frontiers in Neuroscience·Michael KelbermanDavid Weinshenker
Jan 12, 2021·Frontiers in Neuroscience·Amelie SchäferEllen Kuhl
Feb 19, 2021·European Journal of Nuclear Medicine and Molecular Imaging·Yun ZhouTammie L S Benzinger
Sep 14, 2020·Biological Psychiatry·Tengfei GuoUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Mar 31, 2021·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Rachel F Buckley
May 25, 2021·Journal of Alzheimer's Disease : JAD·Mitzi M GonzalesSudha Seshadri
Sep 14, 2021·Frontiers in Systems Neuroscience·Tae-Hyeong KimMin-Hyeon Park

❮ Previous
Next ❯

Software Mentioned

R
MATLAB
FreeSurfer Qdec
lme4
FreeSurfer

Related Concepts

Related Feeds

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.